An investment in a building dedicated to its own research and production
SHANGHAI–(Business Wire)–
On Walloon Biotech Day organised at the Shanghai World Fair, in the Belgian
Pavilion, Delphi Genetics announced its decision today to invest €3.5 million in
a building that will be entirely dedicated to its activity. This 1500m² building
will house the company`s Research & Development Department, its service
activities and the manufacturing of its products. Since July 2006, Delphi
Genetics has been renting an area of 450 square metres in Igretec`s bridging
building in the Charleroi Aeropole Business Park near the Institute of Biology
and Molecular Medicine (IBM) of the Université Libre de Bruxelles (ULB). The new
building, the inauguration of which is envisaged for 2012, will be located in
the ULB`s Biopark, which already contains several Biotech companies.
Dr Cédric Szpirer, Managing Director of Delphi Genetics and one of its founders,
explained: “Delphi Genetics` business is growing: we have more and more contacts
with major companies in the biopharmacy andbiotechnology fields. These contacts
lead to new licensing agreements or partnerships and result in increased
activity in terms of services and production alike. We also have several
research projects underway. We therefore need more space to achieve our
objectives. The new building will enable us to accommodate up to 45 people and
an extension will be possible should it prove to be necessary.”
In June 2009, Delphi Genetics announced a licensing agreement with
Sanofi-Pasteur, Sanofi-Aventis`s human vaccines division. This agreement enables
Sanofi-Pasteur to implement the StabyExpress technology in its production of
recombinant vaccines and therefore to be able to produce them efficiently
without using antibiotic markers.
About Delphi Genetics SA
Founded at the end of 2001, Delphi Genetics develops more effective products and
technologies for genetic engineering and for protein expression in bacteria by
using its unique expertise in the field of plasmid stabilisation systems. Delphi
Genetics` patented Staby technology increases the recombinant protein production
output without the use of antibiotics, which is the traditional approach. For
further information, please visit our website: http://www.delphigenetics.com.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6336170〈=en
Delphi Genetics SA
delphigenetics@delphigenetics.com
Tel: +32 71 25 10 00
Copyright Business Wire 2010